Related Experiment Video
Updated: Sep 19, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Correlations between genetically predicted iron-supplement drug targets and inflammatory bowel disease: A Mendelian
Dong-Lin Li1, Chuan Jiang2, Zhong-An Guan2
1First School of Clinical Medicine, Shandong Traditional Chinese Medicine University, Jinan, Shandong Province, China.
None:
This study investigates the causal relationship between genetically proxied iron-supplement drugs and inflammatory bowel disease (IBD) risk. After identifying 8 commonly used iron supplementation drugs based on the guidelines, a search for each of these drugs yielded 18 key regulatory targets and the locus information of each drug-targeted gene was obtained. Hemoglobin was selected as a biomarker downstream of drug regulation and its single nucleotide polymorphism (SNP) data were extracted and screened from genome-wide association studies (GWAS). Strict screening conditions were set to obtain valid SNPs information for each drug-target gene from hemoglobin downstream marker information. We successively included European and Asian populations in our analyses. The SNP information of IBD, ulcerative colitis (UC) and Crohn disease (CD) were extracted from the GWAS database as the outcome variables. The bidirectional and multivariate Mendelian randomization was performed between each target gene and each outcome variable, and the robustness of these results was validated using heterogeneity tests, horizontal pleiotropy tests, and leave-one-out methods. Data from 34,652 patients with IBD, 417,932 patients with UC, 20,883 patients with CD, and 408,112 individuals with hemoglobin measurement were analyzed. Genetically proxied Egl nine homolog 1 (EGLN1) was associated with increased IBD, UC and CD risk. Genetically proxied Flap Endonuclease 1 (FEN1) was associated with an increased risk of IBD and CD. Genetically proxied Ferritin heavy chain 1 (FTH1) and Transferrin receptor 2 (TFR2) were associated with an increased risk of CD. Genetically proxied DNA polymerase beta (POLB) was associated with a reduced risk of CD. Sensitivity analyses of them did not provide statistical evidence of serious bias. The reverse Mendelian results showed a positive result between IBD and EGLN1, meaning that there is a bidirectional causal relationship between the 2. Upon inclusion of the Asian ethnic cohort, potential causal associations were found between EGLN1, FEN1, Integrin, beta 3 (ITGB3), Transferrin receptor gene (TFRC) and UC, inverse Mendelian analyses showed a causal relationship between POLB and CD. This study suggests that target genes such as EGLN1, FEN1, ITGB3, TFRC, FTH1, and POLB are potentially associated with the pathogenesis of inflammatory bowel disease.
More Related Videos
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
09:04DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF